反応式
Cl.[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][NH:20][CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11].[N:26]1[C:35]2[C:30](=[CH:31][CH:32]=[CH:33][C:34]=2[S:36](Cl)(=[O:38])=[O:37])[CH:29]=[CH:28][CH:27]=1>>[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][N:20]([S:36]([C:34]4[CH:33]=[CH:32][CH:31]=[C:30]5[C:35]=4[N:26]=[CH:27][CH:28]=[CH:29]5)(=[O:37])=[O:38])[CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11]参加物
3
実験手順
The title compound is prepared analogously as described for GP1 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-(piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one hydrochloride (compound B1*HCl) and quinoline-8-sulfonyl chloride as starting compounds. The crude product is purified by crystallization from methanol to yield the title compound.
後処理
- customThe title compound is prepared analogously
- customThe crude product is purified by crystallization from methanol
出典と根拠
- ORDレコード
- ord-4969b166039c4a9a895fce92694f43b1
- 出典データセット
- uspto-grants-2016_05
- 特許番号
- US09340522B2
関連ノート
読み込み中…